Tissue Based Genomic Profiling Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Sequencing Techniques, Immunohistochemistry, Others), By Application (Personalized Medicine, Oncological Diagnostics, Research), By End-User (Research Institutes, Clinical Research Organizations, Hospitals & Clinics, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Others), By Region and Competition, 2019-2029F
Global Tissue Based Genomic Profiling Market was valued at USD 1.37 billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 6.65% through 2029. Tissue-based genomic profiling represents a cutting-edge approach in understanding the genetic makeup of tissues to inform medical decision-making. This advanced technique involves analyzing the genomic alterations within a patient's tissue sample, providing crucial insights into the genetic mutations, alterations, and biomarkers associated with various diseases, especially cancer. By scrutinizing the genomic landscape at a molecular level, tissue-based genomic profiling aids in personalized medicine strategies, guiding clinicians in selecting targeted therapies and predicting treatment responses. This method has proven instrumental in oncology, facilitating the identification of specific genetic abnormalities that drive cancer growth. Tissue-based genomic profiling not only enhances diagnostic accuracy but also holds promise for unraveling the complexities of other diseases, offering a transformative path towards more precise and effective medical interventions tailored to an individual's unique genetic profile.
The Global Tissue-Based Genomic Profiling market is witnessing remarkable growth as a pivotal component of precision medicine. This innovative approach involves the comprehensive analysis of genomic information within tissue samples, enabling a profound understanding of genetic alterations associated with various diseases, particularly cancer. The market is propelled by the increasing adoption of personalized medicine, where the identification of specific genetic biomarkers guides targeted therapy selection. Advancements in genomic technologies, coupled with a growing emphasis on individualized treatment strategies, contribute to the expansion of the Tissue-Based Genomic Profiling market. As a powerful tool in oncology, it facilitates more accurate diagnostics, prognosis, and treatment decisions. With ongoing research and technological advancements, the global Tissue-Based Genomic Profiling market is poised to play a pivotal role in reshaping the landscape of healthcare by offering tailored and effective therapeutic solutions based on an individual's unique genetic profile.
Key Market Drivers
Advancements in Genomic Technologies
Advancements in genomic technologies stand as a cornerstone in propelling the Global Tissue-Based Genomic Profiling market forward, reshaping the landscape of precision medicine. The rapid evolution of sequencing technologies, such as next-generation sequencing (NGS), has revolutionized the analysis of genetic information extracted from tissue samples. These technologies offer unprecedented speed, accuracy, and cost-effectiveness in deciphering the complex genomic makeup of tissues, enabling a comprehensive understanding of genetic alterations associated with diseases.
NGS, in particular, has significantly enhanced the throughput and scalability of genomic profiling, allowing for the simultaneous analysis of multiple genes and pathways. This has proven invaluable in oncology, where the identification of specific mutations and biomarkers informs targeted therapy decisions. The advent of single cell sequencing further refines the resolution, enabling the study of individual cells within a tissue sample, unveiling heterogeneity and providing insights into cellular diversity. Continuous improvements in bioinformatics and data analysis tools complement genomic technologies, facilitating the interpretation of vast datasets generated through tissue-based genomic profiling. Advanced algorithms enhance the identification of clinically relevant genetic alterations, supporting more precise diagnostics and therapeutic interventions. The integration of genomic technologies with other omics data, such as transcriptomics and proteomics, offers a holistic view of the molecular landscape, unraveling intricate interactions and pathways involved in diseases. This integrative approach enhances the depth of information derived from tissue samples, providing a more comprehensive understanding of the underlying biology.
As genomic technologies continue to evolve, with the emergence of third-generation sequencing and enhanced analytical methodologies, the Tissue-Based Genomic Profiling market is poised for further expansion. These technological advancements not only contribute to the scientific understanding of diseases but also hold the promise of unlocking new therapeutic targets, driving personalized medicine approaches, and ultimately improving patient outcomes across various medical specialties. The synergy between technological innovation and genomic profiling opens new frontiers in healthcare, positioning the field at the forefront of medical breakthroughs.
Rising Incidence of Chronic Diseases
The Global Tissue-Based Genomic Profiling market is profoundly influenced by the escalating incidence of chronic diseases, particularly the surging prevalence of cancer. As chronic diseases continue to pose a significant global health burden, the imperative to unravel their molecular underpinnings has intensified, driving the demand for advanced genomic profiling techniques. Cancer is characterized by intricate genetic alterations that dictate disease progression and response to treatment. Tissue-based genomic profiling plays a pivotal role in this context by providing a comprehensive analysis of the genetic landscape within affected tissues. The rising incidence of cancer worldwide underscores the critical need for precise diagnostics and targeted therapies, a demand met by tissue-based genomic profiling.
Beyond cancer, the market is witnessing an expansion into various other chronic diseases, including cardiovascular disorders, neurodegenerative conditions, and autoimmune disorders. As our understanding of the genomic basis of these diseases deepens, the application of tissue-based genomic profiling becomes increasingly vital in guiding therapeutic decisions and predicting disease trajectories. In the realm of oncology, tissue-based genomic profiling is instrumental in identifying actionable mutations and biomarkers, offering a roadmap for personalized treatment strategies. The advent of immunotherapy and targeted therapies necessitates a detailed genomic understanding to match patients with the most efficacious interventions, driving the market's growth. The rising incidence of chronic diseases not only propels the Tissue-Based Genomic Profiling market but also underscores the urgency to transition towards precision medicine.
Tailoring treatments based on an individual's unique genetic profile has the potential to revolutionize patient care, optimizing therapeutic outcomes, and minimizing adverse effects. As the global healthcare landscape grapples with the increasing burden of chronic diseases, tissue-based genomic profiling stands as a beacon of hope, promising a more nuanced and effective approach to diagnosis, treatment, and disease management.
Therapeutic Decision-Making in Oncology
Therapeutic decision-making in oncology has undergone a transformative shift with the advent of tissue-based genomic profiling, positioning itself at the forefront of precision medicine. In the realm of cancer treatment, understanding the genetic alterations driving tumor growth is paramount for tailoring therapies to individual patients. Tissue-based genomic profiling plays a pivotal role in this context, unraveling the complex genomic landscape within cancerous tissues and providing clinicians with invaluable insights into specific mutations and biomarkers. Oncologists, armed with the data from genomic profiling, can make more informed decisions regarding the selection of targeted therapies and immunotherapies.
Identifying actionable mutations allows for the customization of treatment regimens, optimizing the chances of therapeutic success while minimizing potential side effects. The ability to pinpoint genetic abnormalities associated with drug responsiveness or resistance empowers clinicians to choose interventions that align with the unique genetic profile of each patient. The application of tissue-based genomic profiling extends beyond initial diagnosis, influencing treatment monitoring and guiding decisions in the face of disease progression or recurrence. It facilitates real-time adjustments to therapeutic strategies, ensuring a dynamic and personalized approach to patient care.
The integration of tissue-based genomic profiling into clinical trials has become increasingly prevalent, aiding in the identification of suitable candidates based on their genetic makeup. This not only expedites the development of novel targeted therapies but also enhances the efficiency of clinical trial recruitment and outcomes. As therapeutic decision-making in oncology evolves towards a more individualized and precise paradigm, the global Tissue-Based Genomic Profiling market becomes an indispensable ally. Its role in shaping the future of cancer treatment is evident, promising improved patient outcomes, prolonged survival, and a paradigm shift towards more effective and tailored interventions in the fight against this complex and heterogeneous disease.
Key Market Challenges
Lack of Bioinformatics Expertise
The global Tissue-Based Genomic Profiling market encounters a significant challenge related to the demand for specialized bioinformatics expertise. As genomic technologies continue to evolve, the analysis and interpretation of vast and intricate genomic datasets generated through tissue-based profiling necessitate advanced computational skills and bioinformatics proficiency. Bioinformatics serves as the bridge between raw genomic data and clinically actionable insights, playing a pivotal role in deciphering the complex genetic alterations within tissue samples.
One of the primary challenges lies in the scarcity of professionals equipped with the necessary bioinformatics skills. The interdisciplinary nature of bioinformatics requires individuals with a deep understanding of both biological and computational concepts. Addressing this shortage involves initiatives to enhance bioinformatics education and training programs, ensuring a pipeline of skilled professionals capable of navigating the complexities of genomic data analysis. The rapid pace of technological advancements in genomics demands continuous updating of bioinformatics tools and algorithms. Bioinformaticians must stay abreast of evolving methodologies to effectively interpret genomic data and extract meaningful clinical information.
Collaboration between bioinformatics experts, clinicians, and researchers becomes paramount to leverage collective expertise and address the intricate challenges posed by genomic data analysis. Standardization of bioinformatics workflows and methodologies is another critical aspect. Establishing best practices and standardized protocols for genomic data analysis enhances reproducibility and ensures consistency across different laboratories and research institutions. This standardization is essential for fostering interoperability and comparability of genomic data, enabling seamless collaboration and data sharing. In addressing the bioinformatics expertise challenge, the global Tissue-Based Genomic Profiling market stands to benefit from investments in education, training programs, and collaborative initiatives. Empowering a workforce well-versed in both genomics and computational biology is pivotal for unlocking the full potential of tissue-based genomic profiling, ultimately translating complex genetic information into actionable insights for improved patient care.
Clinical Validation and Utility
Clinical validation and utility represent crucial aspects influencing the adoption and success of the global Tissue-Based Genomic Profiling market. While advancements in genomics have provided unprecedented insights into the genetic basis of diseases, demonstrating the clinical validity and utility of genomic profiling is imperative for its integration into routine clinical practice. Clinical validation involves establishing the accuracy and reliability of genomic profiling in identifying genetic alterations associated with specific diseases. Rigorous studies and trials are essential to validate the analytical and clinical performance of genomic profiling technologies, ensuring that the information derived is both accurate and clinically relevant. This validation is particularly crucial in oncology, where tissue-based genomic profiling plays a central role in guiding therapeutic decisions.
Beyond validation, demonstrating the utility of tissue-based genomic profiling in improving patient outcomes is essential. Clinical utility encompasses the impact of genomic information on treatment decisions, patient management, and overall healthcare outcomes. Robust evidence supporting the ability of genomic profiling to guide personalized treatment strategies, predict therapeutic responses, and influence clinical decision-making is vital for garnering acceptance among healthcare providers. The integration of tissue-based genomic profiling into clinical trials further contributes to its validation and utility. Incorporating genomic information in trial designs helps identify patient subgroups likely to respond to specific treatments, expediting drug development and personalized medicine approaches. Challenges arise in navigating the complex landscape of genomic data interpretation and translating genetic insights into actionable clinical strategies. Overcoming these challenges through collaborative research efforts, real-world evidence generation, and the development of standardized guidelines enhances the clinical validity and utility of tissue-based genomic profiling.
Key Market Trends
Advancements in Next-Generation Sequencing (NGS)
Advancements in Next-Generation Sequencing (NGS) have emerged as a cornerstone in revolutionizing the Global Tissue-Based Genomic Profiling market. NGS technologies represent a paradigm shift in genomic analysis, offering unprecedented speed, scalability, and cost-effectiveness compared to traditional sequencing methods. These advancements play a pivotal role in enhancing the depth and breadth of genomic profiling from tissue samples, thereby propelling precision medicine to new heights.
One key aspect of NGS progress is the continuous improvement in sequencing platforms, enabling the generation of vast amounts of data with higher accuracy and reduced turnaround times. The evolution of short-read and long-read sequencing technologies provides researchers and clinicians with versatile tools to explore various genomic complexities. Short-read sequencing facilitates the identification of single nucleotide variations, small insertions, and deletions, while long-read sequencing enhances the detection of structural variations and complex genomic rearrangements. The advent of targeted NGS panels and whole-exome sequencing has refined the focus on relevant genomic regions, allowing for more cost-effective and efficient profiling. This is particularly beneficial in the clinical setting, where targeted sequencing can provide actionable insights for therapeutic decision-making, especially in oncology.
NGS has also enabled the exploration of non-coding regions, such as introns and intergenic regions, unraveling the functional significance of these often-overlooked genomic areas. The comprehensive analysis of both coding and non-coding regions enhances our understanding of the intricate regulatory mechanisms underlying diseases, fostering a more holistic approach to tissue-based genomic profiling.
The integration of NGS with other omics data, such as transcriptomics and epigenomics, facilitates a multi-dimensional understanding of genomic alterations. This holistic approach enhances the identification of potential therapeutic targets and biomarkers for diverse diseases. As NGS technologies continue to evolve, innovations like single-cell sequencing and spatial transcriptomics further expand the capabilities of tissue-based genomic profiling. These advancements not only empower researchers with unprecedented resolution but also pave the way for more precise diagnostics, targeted therapies, and personalized treatment strategies in the dynamic landscape of precision medicine.
Growth in Liquid Biopsy Adoption
The adoption of liquid biopsy represents a transformative trend in the global Tissue-Based Genomic Profiling market, offering a paradigm shift in the way genetic information is obtained and monitored. Liquid biopsy involves the analysis of circulating biomarkers, such as cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), and other nucleic acids present in bodily fluids, eliminating the need for traditional tissue biopsies. This less invasive approach holds particular significance in situations where obtaining tissue samples is challenging or impractical. In oncology, liquid biopsy has gained prominence as a powerful tool for real-time monitoring of tumor dynamics and genetic changes.
The ability to detect ctDNA shed by tumors into the bloodstream provides a comprehensive view of the genetic landscape, allowing for the identification of specific mutations and alterations. This dynamic monitoring is especially valuable for tracking treatment responses, assessing minimal residual disease, and detecting the emergence of resistance mutations over the course of therapy. Liquid biopsy's adoption extends beyond oncology, encompassing applications in prenatal testing, infectious disease diagnostics, and monitoring of organ transplant rejection. In prenatal testing, the analysis of cell-free fetal DNA in maternal blood offers insights into fetal chromosomal abnormalities without the need for invasive procedures. For infectious diseases, the detection of pathogen-derived nucleic acids provides a rapid and non-invasive method for diagnosing infections. The key advantages of liquid biopsy lie in its non-invasiveness, potential for serial monitoring, and the ability to capture the spatial and temporal heterogeneity of tumors.
Liquid biopsy facilitates the analysis of tumor-derived genetic material from metastatic sites that may be challenging to access through traditional biopsies. As liquid biopsy technologies continue to evolve, overcoming challenges related to sensitivity and specificity, they hold immense promise for complementing and, in some cases, even replacing tissue-based genomic profiling. The integration of liquid biopsy into routine clinical practice signifies a transformative trend, offering a more patient-friendly and adaptable approach to genomic analysis with broad implications for precision medicine.
Segmental Insights
Technology Insights
Based on Technology, the Sequencing Techniques emerged as the fastest growing segment in Global Tissue Based Genomic Profiling Market in 2023. This is attributed to its pivotal role in comprehensively analyzing genetic alterations. Next-generation sequencing (NGS) and other advanced sequencing technologies enable the precise identification of mutations, fusions, and other genomic variations in tissue samples. This detailed molecular profiling guides personalized treatment strategies in oncology, driving the prominence of this segment. As these techniques offer high throughput and accuracy, they are preferred for uncovering the complex genomic landscape of tissues in various cancers. The demand for in-depth genomic insights in clinical decision-making solidifies the Sequencing Techniques segment as a key driver in shaping the global landscape of tissue-based genomic profiling.
End User Insights
Based on end user, the hospitals & clinics segment dominated the Global Tissue Based Genomic Profiling Market in 2023. This is because the hospitals and clinics play a central role in the adoption of genomic profiling technologies for precision medicine, particularly in oncology. They possess the necessary infrastructure, expertise, and patient data, facilitating seamless integration of tissue-based genomic profiling into routine clinical practice. The increasing awareness of personalized medicine benefits among healthcare professionals and patients contributes to the segment's dominance. The accessibility and widespread utilization of these services in hospital and clinic settings solidify their leading position in the global market.
Regional Insights
The dominance of the North America segment in the global Tissue-Based Genomic Profiling market stems from various key factors that collectively contribute to its leadership position. North America boasts advanced healthcare infrastructure and substantial investments in research and development (R&D). The region's robust healthcare system enables widespread access to cutting-edge technologies and facilitates the adoption of innovative medical practices, including tissue-based genomic profiling.
The higher prevalence of chronic diseases in North America, such as cancer, cardiovascular diseases, and neurological disorders, has driven the demand for precision medicine. Tissue-based genomic profiling plays a pivotal role in precision medicine by providing personalized insights into the genetic makeup of individual patients, guiding targeted therapies and treatment strategies. North America is home to a myriad of leading biotechnology and pharmaceutical companies that are at the forefront of genomic research and innovation. These companies leverage their expertise and resources to develop and commercialize tissue-based genomic profiling technologies, further driving market growth.
The well-established regulatory framework in North America ensures the safety, efficacy, and quality of genomic profiling technologies. Regulatory agencies such as the Food and Drug Administration (FDA) in the United States play a crucial role in evaluating and approving genomic profiling assays, facilitating their rapid adoption and integration into clinical practice. Collaborative efforts between academic institutions, research organizations, and industry players contribute significantly to advancing genomic research and applications in North America. Collaborative research projects, clinical trials, and knowledge-sharing initiatives foster innovation and drive the development of novel genomic profiling technologies.
North America's leadership in the Tissue-Based Genomic Profiling market is underpinned by its advanced healthcare infrastructure, high disease burden, presence of leading industry players, robust regulatory environment, and collaborative research ecosystem. These factors collectively solidify North America's position as a frontrunner in driving the adoption and advancement of tissue-based genomic profiling technologies, shaping the future of precision medicine in the region and beyond.
Key Market Players
In this report, the Global Tissue Based Genomic Profiling Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
o Immunohistochemistry
o Others
o Oncological Diagnostics
o Research
o Clinical Research Organizations
o Hospitals & Clinics
o Diagnostic Laboratories
o Pharmaceutical & Biotechnology Companies,
o Others
? United States
? Canada
? Mexico
o Europe
? France
? United Kingdom
? Italy
? Germany
? Spain
o Asia Pacific
? China
? India
? Japan
? Australia
? South Korea
o South America
? Brazil
? Argentina
? Colombia
o Middle East & Africa
? South Africa
? Saudi Arabia
? UAE
? Egypt
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Tissue Based Genomic Profiling Market.
Available Customizations:
Global Tissue Based Genomic Profiling Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
The Global Tissue-Based Genomic Profiling market is witnessing remarkable growth as a pivotal component of precision medicine. This innovative approach involves the comprehensive analysis of genomic information within tissue samples, enabling a profound understanding of genetic alterations associated with various diseases, particularly cancer. The market is propelled by the increasing adoption of personalized medicine, where the identification of specific genetic biomarkers guides targeted therapy selection. Advancements in genomic technologies, coupled with a growing emphasis on individualized treatment strategies, contribute to the expansion of the Tissue-Based Genomic Profiling market. As a powerful tool in oncology, it facilitates more accurate diagnostics, prognosis, and treatment decisions. With ongoing research and technological advancements, the global Tissue-Based Genomic Profiling market is poised to play a pivotal role in reshaping the landscape of healthcare by offering tailored and effective therapeutic solutions based on an individual's unique genetic profile.
Key Market Drivers
Advancements in Genomic Technologies
Advancements in genomic technologies stand as a cornerstone in propelling the Global Tissue-Based Genomic Profiling market forward, reshaping the landscape of precision medicine. The rapid evolution of sequencing technologies, such as next-generation sequencing (NGS), has revolutionized the analysis of genetic information extracted from tissue samples. These technologies offer unprecedented speed, accuracy, and cost-effectiveness in deciphering the complex genomic makeup of tissues, enabling a comprehensive understanding of genetic alterations associated with diseases.
NGS, in particular, has significantly enhanced the throughput and scalability of genomic profiling, allowing for the simultaneous analysis of multiple genes and pathways. This has proven invaluable in oncology, where the identification of specific mutations and biomarkers informs targeted therapy decisions. The advent of single cell sequencing further refines the resolution, enabling the study of individual cells within a tissue sample, unveiling heterogeneity and providing insights into cellular diversity. Continuous improvements in bioinformatics and data analysis tools complement genomic technologies, facilitating the interpretation of vast datasets generated through tissue-based genomic profiling. Advanced algorithms enhance the identification of clinically relevant genetic alterations, supporting more precise diagnostics and therapeutic interventions. The integration of genomic technologies with other omics data, such as transcriptomics and proteomics, offers a holistic view of the molecular landscape, unraveling intricate interactions and pathways involved in diseases. This integrative approach enhances the depth of information derived from tissue samples, providing a more comprehensive understanding of the underlying biology.
As genomic technologies continue to evolve, with the emergence of third-generation sequencing and enhanced analytical methodologies, the Tissue-Based Genomic Profiling market is poised for further expansion. These technological advancements not only contribute to the scientific understanding of diseases but also hold the promise of unlocking new therapeutic targets, driving personalized medicine approaches, and ultimately improving patient outcomes across various medical specialties. The synergy between technological innovation and genomic profiling opens new frontiers in healthcare, positioning the field at the forefront of medical breakthroughs.
Rising Incidence of Chronic Diseases
The Global Tissue-Based Genomic Profiling market is profoundly influenced by the escalating incidence of chronic diseases, particularly the surging prevalence of cancer. As chronic diseases continue to pose a significant global health burden, the imperative to unravel their molecular underpinnings has intensified, driving the demand for advanced genomic profiling techniques. Cancer is characterized by intricate genetic alterations that dictate disease progression and response to treatment. Tissue-based genomic profiling plays a pivotal role in this context by providing a comprehensive analysis of the genetic landscape within affected tissues. The rising incidence of cancer worldwide underscores the critical need for precise diagnostics and targeted therapies, a demand met by tissue-based genomic profiling.
Beyond cancer, the market is witnessing an expansion into various other chronic diseases, including cardiovascular disorders, neurodegenerative conditions, and autoimmune disorders. As our understanding of the genomic basis of these diseases deepens, the application of tissue-based genomic profiling becomes increasingly vital in guiding therapeutic decisions and predicting disease trajectories. In the realm of oncology, tissue-based genomic profiling is instrumental in identifying actionable mutations and biomarkers, offering a roadmap for personalized treatment strategies. The advent of immunotherapy and targeted therapies necessitates a detailed genomic understanding to match patients with the most efficacious interventions, driving the market's growth. The rising incidence of chronic diseases not only propels the Tissue-Based Genomic Profiling market but also underscores the urgency to transition towards precision medicine.
Tailoring treatments based on an individual's unique genetic profile has the potential to revolutionize patient care, optimizing therapeutic outcomes, and minimizing adverse effects. As the global healthcare landscape grapples with the increasing burden of chronic diseases, tissue-based genomic profiling stands as a beacon of hope, promising a more nuanced and effective approach to diagnosis, treatment, and disease management.
Therapeutic Decision-Making in Oncology
Therapeutic decision-making in oncology has undergone a transformative shift with the advent of tissue-based genomic profiling, positioning itself at the forefront of precision medicine. In the realm of cancer treatment, understanding the genetic alterations driving tumor growth is paramount for tailoring therapies to individual patients. Tissue-based genomic profiling plays a pivotal role in this context, unraveling the complex genomic landscape within cancerous tissues and providing clinicians with invaluable insights into specific mutations and biomarkers. Oncologists, armed with the data from genomic profiling, can make more informed decisions regarding the selection of targeted therapies and immunotherapies.
Identifying actionable mutations allows for the customization of treatment regimens, optimizing the chances of therapeutic success while minimizing potential side effects. The ability to pinpoint genetic abnormalities associated with drug responsiveness or resistance empowers clinicians to choose interventions that align with the unique genetic profile of each patient. The application of tissue-based genomic profiling extends beyond initial diagnosis, influencing treatment monitoring and guiding decisions in the face of disease progression or recurrence. It facilitates real-time adjustments to therapeutic strategies, ensuring a dynamic and personalized approach to patient care.
The integration of tissue-based genomic profiling into clinical trials has become increasingly prevalent, aiding in the identification of suitable candidates based on their genetic makeup. This not only expedites the development of novel targeted therapies but also enhances the efficiency of clinical trial recruitment and outcomes. As therapeutic decision-making in oncology evolves towards a more individualized and precise paradigm, the global Tissue-Based Genomic Profiling market becomes an indispensable ally. Its role in shaping the future of cancer treatment is evident, promising improved patient outcomes, prolonged survival, and a paradigm shift towards more effective and tailored interventions in the fight against this complex and heterogeneous disease.
Key Market Challenges
Lack of Bioinformatics Expertise
The global Tissue-Based Genomic Profiling market encounters a significant challenge related to the demand for specialized bioinformatics expertise. As genomic technologies continue to evolve, the analysis and interpretation of vast and intricate genomic datasets generated through tissue-based profiling necessitate advanced computational skills and bioinformatics proficiency. Bioinformatics serves as the bridge between raw genomic data and clinically actionable insights, playing a pivotal role in deciphering the complex genetic alterations within tissue samples.
One of the primary challenges lies in the scarcity of professionals equipped with the necessary bioinformatics skills. The interdisciplinary nature of bioinformatics requires individuals with a deep understanding of both biological and computational concepts. Addressing this shortage involves initiatives to enhance bioinformatics education and training programs, ensuring a pipeline of skilled professionals capable of navigating the complexities of genomic data analysis. The rapid pace of technological advancements in genomics demands continuous updating of bioinformatics tools and algorithms. Bioinformaticians must stay abreast of evolving methodologies to effectively interpret genomic data and extract meaningful clinical information.
Collaboration between bioinformatics experts, clinicians, and researchers becomes paramount to leverage collective expertise and address the intricate challenges posed by genomic data analysis. Standardization of bioinformatics workflows and methodologies is another critical aspect. Establishing best practices and standardized protocols for genomic data analysis enhances reproducibility and ensures consistency across different laboratories and research institutions. This standardization is essential for fostering interoperability and comparability of genomic data, enabling seamless collaboration and data sharing. In addressing the bioinformatics expertise challenge, the global Tissue-Based Genomic Profiling market stands to benefit from investments in education, training programs, and collaborative initiatives. Empowering a workforce well-versed in both genomics and computational biology is pivotal for unlocking the full potential of tissue-based genomic profiling, ultimately translating complex genetic information into actionable insights for improved patient care.
Clinical Validation and Utility
Clinical validation and utility represent crucial aspects influencing the adoption and success of the global Tissue-Based Genomic Profiling market. While advancements in genomics have provided unprecedented insights into the genetic basis of diseases, demonstrating the clinical validity and utility of genomic profiling is imperative for its integration into routine clinical practice. Clinical validation involves establishing the accuracy and reliability of genomic profiling in identifying genetic alterations associated with specific diseases. Rigorous studies and trials are essential to validate the analytical and clinical performance of genomic profiling technologies, ensuring that the information derived is both accurate and clinically relevant. This validation is particularly crucial in oncology, where tissue-based genomic profiling plays a central role in guiding therapeutic decisions.
Beyond validation, demonstrating the utility of tissue-based genomic profiling in improving patient outcomes is essential. Clinical utility encompasses the impact of genomic information on treatment decisions, patient management, and overall healthcare outcomes. Robust evidence supporting the ability of genomic profiling to guide personalized treatment strategies, predict therapeutic responses, and influence clinical decision-making is vital for garnering acceptance among healthcare providers. The integration of tissue-based genomic profiling into clinical trials further contributes to its validation and utility. Incorporating genomic information in trial designs helps identify patient subgroups likely to respond to specific treatments, expediting drug development and personalized medicine approaches. Challenges arise in navigating the complex landscape of genomic data interpretation and translating genetic insights into actionable clinical strategies. Overcoming these challenges through collaborative research efforts, real-world evidence generation, and the development of standardized guidelines enhances the clinical validity and utility of tissue-based genomic profiling.
Key Market Trends
Advancements in Next-Generation Sequencing (NGS)
Advancements in Next-Generation Sequencing (NGS) have emerged as a cornerstone in revolutionizing the Global Tissue-Based Genomic Profiling market. NGS technologies represent a paradigm shift in genomic analysis, offering unprecedented speed, scalability, and cost-effectiveness compared to traditional sequencing methods. These advancements play a pivotal role in enhancing the depth and breadth of genomic profiling from tissue samples, thereby propelling precision medicine to new heights.
One key aspect of NGS progress is the continuous improvement in sequencing platforms, enabling the generation of vast amounts of data with higher accuracy and reduced turnaround times. The evolution of short-read and long-read sequencing technologies provides researchers and clinicians with versatile tools to explore various genomic complexities. Short-read sequencing facilitates the identification of single nucleotide variations, small insertions, and deletions, while long-read sequencing enhances the detection of structural variations and complex genomic rearrangements. The advent of targeted NGS panels and whole-exome sequencing has refined the focus on relevant genomic regions, allowing for more cost-effective and efficient profiling. This is particularly beneficial in the clinical setting, where targeted sequencing can provide actionable insights for therapeutic decision-making, especially in oncology.
NGS has also enabled the exploration of non-coding regions, such as introns and intergenic regions, unraveling the functional significance of these often-overlooked genomic areas. The comprehensive analysis of both coding and non-coding regions enhances our understanding of the intricate regulatory mechanisms underlying diseases, fostering a more holistic approach to tissue-based genomic profiling.
The integration of NGS with other omics data, such as transcriptomics and epigenomics, facilitates a multi-dimensional understanding of genomic alterations. This holistic approach enhances the identification of potential therapeutic targets and biomarkers for diverse diseases. As NGS technologies continue to evolve, innovations like single-cell sequencing and spatial transcriptomics further expand the capabilities of tissue-based genomic profiling. These advancements not only empower researchers with unprecedented resolution but also pave the way for more precise diagnostics, targeted therapies, and personalized treatment strategies in the dynamic landscape of precision medicine.
Growth in Liquid Biopsy Adoption
The adoption of liquid biopsy represents a transformative trend in the global Tissue-Based Genomic Profiling market, offering a paradigm shift in the way genetic information is obtained and monitored. Liquid biopsy involves the analysis of circulating biomarkers, such as cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), and other nucleic acids present in bodily fluids, eliminating the need for traditional tissue biopsies. This less invasive approach holds particular significance in situations where obtaining tissue samples is challenging or impractical. In oncology, liquid biopsy has gained prominence as a powerful tool for real-time monitoring of tumor dynamics and genetic changes.
The ability to detect ctDNA shed by tumors into the bloodstream provides a comprehensive view of the genetic landscape, allowing for the identification of specific mutations and alterations. This dynamic monitoring is especially valuable for tracking treatment responses, assessing minimal residual disease, and detecting the emergence of resistance mutations over the course of therapy. Liquid biopsy's adoption extends beyond oncology, encompassing applications in prenatal testing, infectious disease diagnostics, and monitoring of organ transplant rejection. In prenatal testing, the analysis of cell-free fetal DNA in maternal blood offers insights into fetal chromosomal abnormalities without the need for invasive procedures. For infectious diseases, the detection of pathogen-derived nucleic acids provides a rapid and non-invasive method for diagnosing infections. The key advantages of liquid biopsy lie in its non-invasiveness, potential for serial monitoring, and the ability to capture the spatial and temporal heterogeneity of tumors.
Liquid biopsy facilitates the analysis of tumor-derived genetic material from metastatic sites that may be challenging to access through traditional biopsies. As liquid biopsy technologies continue to evolve, overcoming challenges related to sensitivity and specificity, they hold immense promise for complementing and, in some cases, even replacing tissue-based genomic profiling. The integration of liquid biopsy into routine clinical practice signifies a transformative trend, offering a more patient-friendly and adaptable approach to genomic analysis with broad implications for precision medicine.
Segmental Insights
Technology Insights
Based on Technology, the Sequencing Techniques emerged as the fastest growing segment in Global Tissue Based Genomic Profiling Market in 2023. This is attributed to its pivotal role in comprehensively analyzing genetic alterations. Next-generation sequencing (NGS) and other advanced sequencing technologies enable the precise identification of mutations, fusions, and other genomic variations in tissue samples. This detailed molecular profiling guides personalized treatment strategies in oncology, driving the prominence of this segment. As these techniques offer high throughput and accuracy, they are preferred for uncovering the complex genomic landscape of tissues in various cancers. The demand for in-depth genomic insights in clinical decision-making solidifies the Sequencing Techniques segment as a key driver in shaping the global landscape of tissue-based genomic profiling.
End User Insights
Based on end user, the hospitals & clinics segment dominated the Global Tissue Based Genomic Profiling Market in 2023. This is because the hospitals and clinics play a central role in the adoption of genomic profiling technologies for precision medicine, particularly in oncology. They possess the necessary infrastructure, expertise, and patient data, facilitating seamless integration of tissue-based genomic profiling into routine clinical practice. The increasing awareness of personalized medicine benefits among healthcare professionals and patients contributes to the segment's dominance. The accessibility and widespread utilization of these services in hospital and clinic settings solidify their leading position in the global market.
Regional Insights
The dominance of the North America segment in the global Tissue-Based Genomic Profiling market stems from various key factors that collectively contribute to its leadership position. North America boasts advanced healthcare infrastructure and substantial investments in research and development (R&D). The region's robust healthcare system enables widespread access to cutting-edge technologies and facilitates the adoption of innovative medical practices, including tissue-based genomic profiling.
The higher prevalence of chronic diseases in North America, such as cancer, cardiovascular diseases, and neurological disorders, has driven the demand for precision medicine. Tissue-based genomic profiling plays a pivotal role in precision medicine by providing personalized insights into the genetic makeup of individual patients, guiding targeted therapies and treatment strategies. North America is home to a myriad of leading biotechnology and pharmaceutical companies that are at the forefront of genomic research and innovation. These companies leverage their expertise and resources to develop and commercialize tissue-based genomic profiling technologies, further driving market growth.
The well-established regulatory framework in North America ensures the safety, efficacy, and quality of genomic profiling technologies. Regulatory agencies such as the Food and Drug Administration (FDA) in the United States play a crucial role in evaluating and approving genomic profiling assays, facilitating their rapid adoption and integration into clinical practice. Collaborative efforts between academic institutions, research organizations, and industry players contribute significantly to advancing genomic research and applications in North America. Collaborative research projects, clinical trials, and knowledge-sharing initiatives foster innovation and drive the development of novel genomic profiling technologies.
North America's leadership in the Tissue-Based Genomic Profiling market is underpinned by its advanced healthcare infrastructure, high disease burden, presence of leading industry players, robust regulatory environment, and collaborative research ecosystem. These factors collectively solidify North America's position as a frontrunner in driving the adoption and advancement of tissue-based genomic profiling technologies, shaping the future of precision medicine in the region and beyond.
Key Market Players
- Foundation Medicine Inc
- Illumina, Inc.
- QIAGEN N.V.
- Roche Diagnostics Corp
- Thermo Fisher Scientific Inc.
- Exact Sciences Corp
- Personal Genome Diagnostics Inc.
In this report, the Global Tissue Based Genomic Profiling Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Tissue Based Genomic Profiling Market, By Technology:
o Immunohistochemistry
o Others
- Tissue Based Genomic Profiling Market, By Application:
o Oncological Diagnostics
o Research
- Tissue Based Genomic Profiling Market, By End user:
o Clinical Research Organizations
o Hospitals & Clinics
o Diagnostic Laboratories
o Pharmaceutical & Biotechnology Companies,
o Others
- Tissue Based Genomic Profiling Market, By Region:
? United States
? Canada
? Mexico
o Europe
? France
? United Kingdom
? Italy
? Germany
? Spain
o Asia Pacific
? China
? India
? Japan
? Australia
? South Korea
o South America
? Brazil
? Argentina
? Colombia
o Middle East & Africa
? South Africa
? Saudi Arabia
? UAE
? Egypt
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Tissue Based Genomic Profiling Market.
Available Customizations:
Global Tissue Based Genomic Profiling Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL TISSUE BASED GENOMIC PROFILING MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Technology (Sequencing Techniques, Immunohistochemistry, Others)
5.2.2. By Application (Personalized Medicine, Oncological Diagnostics, Research)
5.2.3. By End-User (Research Institutes, Clinical Research Organizations, Hospitals & Clinics, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Others)
5.2.4. By Region
5.2.5. By Company (2023)
5.3. Market Map
5.3.1. By Technology
5.3.2. By Application
5.3.3. By End-User
5.3.4. By Region
6. ASIA PACIFIC TISSUE BASED GENOMIC PROFILING MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Technology
6.2.2. By Application
6.2.3. By End-User
6.2.4. By Country
6.3. Asia Pacific: Country Analysis
6.3.1. China Tissue Based Genomic Profiling Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Technology
6.3.1.2.2. By Application
6.3.1.2.3. By End-User
6.3.2. India Tissue Based Genomic Profiling Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Technology
6.3.2.2.2. By Application
6.3.2.2.3. By End-User
6.3.3. Australia Tissue Based Genomic Profiling Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Technology
6.3.3.2.2. By Application
6.3.3.2.3. By End-User
6.3.4. Japan Tissue Based Genomic Profiling Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Technology
6.3.4.2.2. By Application
6.3.4.2.3. By End-User
6.3.5. South Korea Tissue Based Genomic Profiling Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Technology
6.3.5.2.2. By Application
6.3.5.2.3. By End-User
7. EUROPE TISSUE BASED GENOMIC PROFILING MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Technology
7.2.2. By Application
7.2.3. By End-User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France Tissue Based Genomic Profiling Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Technology
7.3.1.2.2. By Application
7.3.1.2.3. By End-User
7.3.2. Germany Tissue Based Genomic Profiling Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Technology
7.3.2.2.2. By Application
7.3.2.2.3. By End-User
7.3.3. Spain Tissue Based Genomic Profiling Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Technology
7.3.3.2.2. By Application
7.3.3.2.3. By End-User
7.3.4. Italy Tissue Based Genomic Profiling Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Technology
7.3.4.2.2. By Application
7.3.4.2.3. By End-User
7.3.5. United Kingdom Tissue Based Genomic Profiling Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Technology
7.3.5.2.2. By Application
7.3.5.2.3. By End-User
8. NORTH AMERICA TISSUE BASED GENOMIC PROFILING MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Technology
8.2.2. By Application
8.2.3. By End-User
8.2.4. By Country
8.3. North America: Country Analysis
8.3.1. United States Tissue Based Genomic Profiling Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Technology
8.3.1.2.2. By Application
8.3.1.2.3. By End-User
8.3.2. Mexico Tissue Based Genomic Profiling Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Technology
8.3.2.2.2. By Application
8.3.2.2.3. By End-User
8.3.3. Canada Tissue Based Genomic Profiling Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Technology
8.3.3.2.2. By Application
8.3.3.2.3. By End-User
9. SOUTH AMERICA TISSUE BASED GENOMIC PROFILING MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Technology
9.2.2. By Application
9.2.3. By End-User
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Tissue Based Genomic Profiling Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Technology
9.3.1.2.2. By Application
9.3.1.2.3. By End-User
9.3.2. Argentina Tissue Based Genomic Profiling Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Technology
9.3.2.2.2. By Application
9.3.2.2.3. By End-User
9.3.3. Colombia Tissue Based Genomic Profiling Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Technology
9.3.3.2.2. By Application
9.3.3.2.3. By End-User
10. MIDDLE EAST AND AFRICA TISSUE BASED GENOMIC PROFILING MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Technology
10.2.2. By Application
10.2.3. By End-User
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Tissue Based Genomic Profiling Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Technology
10.3.1.2.2. By Application
10.3.1.2.3. By End-User
10.3.2. Saudi Arabia Tissue Based Genomic Profiling Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Technology
10.3.2.2.2. By Application
10.3.2.2.3. By End-User
10.3.3. UAE Tissue Based Genomic Profiling Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Technology
10.3.3.2.2. By Application
10.3.3.2.3. By End-User
10.3.4. Egypt Tissue Based Genomic Profiling Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Technology
10.3.4.2.2. By Application
10.3.4.2.3. By End-User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. GLOBAL TISSUE BASED GENOMIC PROFILING MARKET: SWOT ANALYSIS
14. PORTER’S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. COMPETITIVE LANDSCAPE
15.1. Foundation Medicine Inc
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.3. Products & Services
15.1.4. Financials (In case of listed)
15.1.5. Recent Developments
15.1.6. SWOT Analysis
15.2. Illumina, Inc.
15.3. QIAGEN N.V.
15.4. Roche Diagnostics Corp
15.5. Thermo Fisher Scientific Inc.
15.6. Exact Sciences Corp
15.7. Personal Genome Diagnostics Inc.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL TISSUE BASED GENOMIC PROFILING MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Technology (Sequencing Techniques, Immunohistochemistry, Others)
5.2.2. By Application (Personalized Medicine, Oncological Diagnostics, Research)
5.2.3. By End-User (Research Institutes, Clinical Research Organizations, Hospitals & Clinics, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Others)
5.2.4. By Region
5.2.5. By Company (2023)
5.3. Market Map
5.3.1. By Technology
5.3.2. By Application
5.3.3. By End-User
5.3.4. By Region
6. ASIA PACIFIC TISSUE BASED GENOMIC PROFILING MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Technology
6.2.2. By Application
6.2.3. By End-User
6.2.4. By Country
6.3. Asia Pacific: Country Analysis
6.3.1. China Tissue Based Genomic Profiling Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Technology
6.3.1.2.2. By Application
6.3.1.2.3. By End-User
6.3.2. India Tissue Based Genomic Profiling Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Technology
6.3.2.2.2. By Application
6.3.2.2.3. By End-User
6.3.3. Australia Tissue Based Genomic Profiling Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Technology
6.3.3.2.2. By Application
6.3.3.2.3. By End-User
6.3.4. Japan Tissue Based Genomic Profiling Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Technology
6.3.4.2.2. By Application
6.3.4.2.3. By End-User
6.3.5. South Korea Tissue Based Genomic Profiling Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Technology
6.3.5.2.2. By Application
6.3.5.2.3. By End-User
7. EUROPE TISSUE BASED GENOMIC PROFILING MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Technology
7.2.2. By Application
7.2.3. By End-User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France Tissue Based Genomic Profiling Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Technology
7.3.1.2.2. By Application
7.3.1.2.3. By End-User
7.3.2. Germany Tissue Based Genomic Profiling Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Technology
7.3.2.2.2. By Application
7.3.2.2.3. By End-User
7.3.3. Spain Tissue Based Genomic Profiling Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Technology
7.3.3.2.2. By Application
7.3.3.2.3. By End-User
7.3.4. Italy Tissue Based Genomic Profiling Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Technology
7.3.4.2.2. By Application
7.3.4.2.3. By End-User
7.3.5. United Kingdom Tissue Based Genomic Profiling Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Technology
7.3.5.2.2. By Application
7.3.5.2.3. By End-User
8. NORTH AMERICA TISSUE BASED GENOMIC PROFILING MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Technology
8.2.2. By Application
8.2.3. By End-User
8.2.4. By Country
8.3. North America: Country Analysis
8.3.1. United States Tissue Based Genomic Profiling Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Technology
8.3.1.2.2. By Application
8.3.1.2.3. By End-User
8.3.2. Mexico Tissue Based Genomic Profiling Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Technology
8.3.2.2.2. By Application
8.3.2.2.3. By End-User
8.3.3. Canada Tissue Based Genomic Profiling Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Technology
8.3.3.2.2. By Application
8.3.3.2.3. By End-User
9. SOUTH AMERICA TISSUE BASED GENOMIC PROFILING MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Technology
9.2.2. By Application
9.2.3. By End-User
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Tissue Based Genomic Profiling Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Technology
9.3.1.2.2. By Application
9.3.1.2.3. By End-User
9.3.2. Argentina Tissue Based Genomic Profiling Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Technology
9.3.2.2.2. By Application
9.3.2.2.3. By End-User
9.3.3. Colombia Tissue Based Genomic Profiling Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Technology
9.3.3.2.2. By Application
9.3.3.2.3. By End-User
10. MIDDLE EAST AND AFRICA TISSUE BASED GENOMIC PROFILING MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Technology
10.2.2. By Application
10.2.3. By End-User
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Tissue Based Genomic Profiling Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Technology
10.3.1.2.2. By Application
10.3.1.2.3. By End-User
10.3.2. Saudi Arabia Tissue Based Genomic Profiling Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Technology
10.3.2.2.2. By Application
10.3.2.2.3. By End-User
10.3.3. UAE Tissue Based Genomic Profiling Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Technology
10.3.3.2.2. By Application
10.3.3.2.3. By End-User
10.3.4. Egypt Tissue Based Genomic Profiling Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Technology
10.3.4.2.2. By Application
10.3.4.2.3. By End-User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. GLOBAL TISSUE BASED GENOMIC PROFILING MARKET: SWOT ANALYSIS
14. PORTER’S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. COMPETITIVE LANDSCAPE
15.1. Foundation Medicine Inc
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.3. Products & Services
15.1.4. Financials (In case of listed)
15.1.5. Recent Developments
15.1.6. SWOT Analysis
15.2. Illumina, Inc.
15.3. QIAGEN N.V.
15.4. Roche Diagnostics Corp
15.5. Thermo Fisher Scientific Inc.
15.6. Exact Sciences Corp
15.7. Personal Genome Diagnostics Inc.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
